Cholecystokinin

Summary

Cholecystokinin (CCK) is a gastrointestinal hormone and neuropeptide that stimulates gallbladder contraction, pancreatic enzyme release, and signals satiety. It is studied primarily for its role in appetite regulation, digestion, and emerging interest in pain modulation. Research uses intravenous or subcutaneous administration of CCK or analogues to assess effects on food intake and related hormonal responses.

Mechanism of Action

CCK acts through two G‑protein‑coupled receptors: CCK1R (predominantly peripheral) and CCK2R (central and peripheral). Binding to CCK1R in the hindbrain activates vagal afferents that promote satiety, suppress orexigenic neuropeptides, and blunt ghrelin‑driven hunger. CCK1R also triggers gallbladder contraction and pancreatic enzyme secretion. CCK2R mediates central effects on pain pathways and interacts with opioid signaling. Both receptors signal via phospholipase C and intracellular calcium, leading to short‑term digestive responses and longer‑term modulation of appetite‑related circuits.

What the Research Shows

A randomized trial in women with lipedema found that an 8‑week low‑carbohydrate diet reduced post‑prandial ghrelin and increased fullness, while both low‑carbohydrate and low‑fat diets lowered post‑prandial CCK levels. A meta‑analysis of protein feeding showed acute protein doses (≥35 g) raise CCK by ~30 pg/mL and suppress hunger. A systematic review and meta‑analysis of CCK infusion studies (15 trials) demonstrated that physiological and pharmacological CCK dosing significantly reduced food intake (standardised mean differences 0.57 and 0.91, respectively), though no long‑term weight loss was observed. A mini‑review highlighted CCK2R as a target in chronic pain, noting limited clinical success but renewed interest in novel modulators. Overall, evidence supports CCK’s acute satiety‑inducing effects but remains inconclusive for sustained weight management or pain therapy.

Reported Benefits

Evidence from infusion studies and protein‑challenge trials indicates that CCK can acutely increase feelings of fullness and decrease food intake, suggesting utility in short‑term appetite control. CCK also participates in digestive processes such as gallbladder contraction and pancreatic enzyme secretion, which may be beneficial in research settings examining gastrointestinal function. Preliminary data on CCK2R imply potential relevance for pain modulation, though clinical benefits are not yet established.

Limitations of the Evidence

Long‑term outcomes are unclear; systematic reviews found no sustained weight loss despite acute reductions in intake. Oral CCK analogues have failed to produce weight change over 24 weeks. Pain‑related findings are limited to preclinical or early‑phase reports, with mixed efficacy. Most human data derive from short‑term infusion or dietary challenge studies, and the heterogeneity of protocols hampers definitive conclusions about therapeutic value.

Safety Considerations

Safety information in the cited literature is sparse. CCK’s physiological actions (gallbladder contraction, pancreatic secretion) could provoke discomfort, nausea, or exacerbate gallstone disease in susceptible individuals. The lack of adverse‑event reporting in the reviewed trials suggests tolerability in controlled settings, but broader safety data are limited, warranting caution in subjects with biliary or pancreatic disorders.

How It Is Administered

Research use of CCK is typically via intravenous or subcutaneous routes, often as short infusions of the peptide or synthetic analogues. Formulations are administered in controlled clinical settings, sometimes combined with gastric distension techniques to enhance satiation measurements.

Routes of Administration

Goals & Uses

• induce gallbladder contractionDiagnosticHigh
• Pancreatic function testingDiagnosticHigh
• promote satietyMetabolicModerate
• Anxiety and panic disorder modulationNeuropsychiatricLow
• Gallbladder visualization (cholecystography)DiagnosticHigh
• stimulate pancreatic enzyme secretionPhysiologicalHigh
• Gastroparesis / GI motilityGastrointestinalLow
• Appetite suppression / satietyMetabolicModerate

Contraindications

• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Biliary obstructionBiliaryHigh
• Acute pancreatitisGastrointestinalHigh
• severe gastrointestinal obstructionGastrointestinalHigh
• Hypersensitivity to CCK or sincalideAllergyHigh

Adverse Effects

• AnaphylaxisImmunologicRareSevere life-threatening allergic reaction
• HypotensionCardiovascularUncommonLow blood pressure
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Panic attacks (CCK-4 fragment)NeuropsychiatricCommon
• Abdominal cramping / painGastrointestinalCommon
• DiarrheaGastrointestinalUncommonLoose or frequent stools
• Abdominal painGastrointestinalCommonPain or discomfort in the abdomen

Drug Interactions

• Calcium channel blockersLow
• Anticholinergic agentsModerate
• Opioid analgesicsModerate
• somatostatin analogsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant womenReproductiveRelative
• Patients with anxiety disordersPsychiatricRelative

Regulatory Status

• European UnionUnapprovedNo marketing authorization; used in research.
• United StatesUnapprovedInvestigational peptide, not FDA‑approved for therapeutic use.
• United KingdomUnknownNo current MHRA-approved CCK therapeutic product identified; used mainly in research and diagnostics.

Not approved as a therapeutic agent; primarily used in pre‑clinical and clinical research settings.

Evidence & Sources

• Gastrointestinal hormones and subjective ratings of appetite after low-carbohydrate vs low-fat low-energy diets in females with lipedema - A randomized controlled trial
  Journal ArticleModerateLundanes J, et al.2025-01-01T00:00:00.000000Z
• Cholecystokinin
  Journal ArticleModerateChandra R, Liddle RA2007-01-01T00:00:00.000000Z
• Effect of short- and long-term protein consumption on appetite and appetite-regulating gastrointestinal hormones, a systematic review and meta-analysis of randomized controlled trials
  Journal ArticleHighKohanmoo A, Faghih S, Akhlaghi M2020-01-01T00:00:00.000000Z
• Role of cholecystokinin in satiation: a systematic review and meta-analysis
  Journal ArticleHighWarrilow A, et al.2023-01-01T00:00:00.000000Z
• Cholecystokinin and gastrin receptors
  Journal ArticleModerateDufresne M, Seva C, Fourmy D2006-01-01T00:00:00.000000Z
• CCK2 receptors in chronic pain
  Journal ArticleModerateLaVigne JE, Alles SRA2022-01-01T00:00:00.000000Z

Frequently Asked Questions